BeOne Medicines Ltd.
ONCAPI behind this page
ONC Q1 2026 request
Playground key active
/api/financials?ticker=ONC&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 1,513,438 | 1,117,279 | +35.5% |
Show Product Lines breakouts |
|||
| Amgen royalty revenue · Novartis | 18,297 | 5,519 | +231.5% |
| Novartis broad markets revenue · Novartis | 5,263 | 3,522 | +49.4% |
| Other Revenue | 26,109 | 8,749 | +198.4% |
| Other Revenue · CN | 6,792 | 3,230 | +110.3% |
| Other Revenue · Europe | 2,675 | 1,656 | +61.5% |
| Other Revenue · Novartis | 26,109 | 8,749 | +198.4% |
| Other Revenue · US | 16,642 | 3,863 | +330.8% |
| Other · Novartis | 2,549 | -292 | +972.9% |
| Product | 1,487,329 | 1,108,530 | +34.2% |
| Product · BLINCYTO | 34,035 | 23,906 | +42.4% |
| Product · BRUKINSA | 1,094,843 | 791,664 | +38.3% |
| Product · CN | 465,182 | 396,362 | +17.4% |
| Product · Europe | 191,321 | 116,898 | +63.7% |
| Product · KYPROLIS | 16,971 | 19,728 | -14.0% |
| Product · Other | 33,192 | 17,900 | +85.4% |
| Product · POBEVCY | 12,127 | 13,745 | -11.8% |
| Product · Rest of world - total revenue | 65,213 | 31,922 | +104.3% |
| Product · TEVIMBRA | 206,241 | 171,164 | +20.5% |
| Product · US | 765,613 | 563,348 | +35.9% |
| Product · XGEVA | 89,920 | 70,423 | +27.7% |
Show Geography breakouts |
|||
| CN | 471,974 | 399,592 | +18.1% |
| Europe | 193,996 | 118,554 | +63.6% |
| Rest of world - total revenue | 65,213 | 31,922 | +104.3% |
| US | 782,255 | 567,211 | +37.9% |
| Cost of Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 167,215 | 165,002 | +1.3% |
| Gross Profit | 1,346,223 | 952,277 | +41.4% |
| Research & Development | 541,224 | 481,887 | +12.3% |
Show Counterparty Name breakouts |
|||
| Amgen, Inc | 29,403 | 20,707 | +42.0% |
| Selling, General & Administrative | 555,097 | 459,288 | +20.9% |
| Total Costs & Expenses | 1,096,321 | 941,175 | +16.5% |
| Operating Income | 249,902 | 11,102 | +2151.0% |
| Interest Income | 27,664 | 12,850 | +115.3% |
| Interest Expense | -32,887 | -7,002 | -369.7% |
| Other Non-Operating Income (Expense) | 14,536 | 3,950 | +268.0% |
| Income Before Taxes | 259,215 | 20,900 | +1140.3% |
| Income Tax Expense (Benefit) | 31,858 | 19,630 | +62.3% |
| Net Income | 227,357 | 1,270 | +17802.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | 227,357 | 1,270 | +17802.1% |
| EPS (Basic) | 0.16 | 0 | — |
| EPS (Diluted) | 0.15 | 0 | — |
| Wtd Avg Shares (Basic) | 1,442,451,870 | 1,390,052,966 | +3.8% |
| Wtd Avg Shares (Diluted) | 1,505,027,338 | 1,445,253,219 | +4.1% |
| Earnings Per American Depository Share Basic | 2.05 | 0.01 | +20400.0% |
| Earnings Per American Depository Share Diluted | 1.96 | 0.01 | +19500.0% |
| Weighted Average Number Of American Depository Shares Outstanding Basic | 110,957,836 | 106,927,151 | +3.8% |
| Weighted Average Number Of American Depository Shares Outstanding Diluted | 115,771,334 | 111,173,325 | +4.1% |
| Comprehensive Income | 252,059 | 7,937 | +3075.7% |
| Other Comprehensive Income | 24,702 | 6,667 | +270.5% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 24,702 | 6,667 | +270.5% |
| Income Loss From Equity Method Investments (Q) | — | — | — |
Show Income Statement Location breakouts |
|||
| Other Operating Income Expense | -5 | -13,375 | +100.0% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 4,791,676 | 2,516,411 | +90.4% |
| Accounts Receivable | 938,019 | 717,239 | +30.8% |
| Inventory | 681,590 | — | — |
| Prepaid Expenses & Other Current Assets | 189,995 | 168,182 | +13.0% |
| Total Current Assets | 6,601,280 | 3,896,492 | +69.4% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 1,640,918 | 1,598,588 | +2.6% |
| Operating Lease Right-of-Use Assets | 145,497 | 146,416 | -0.6% |
| Intangible Assets | 61,681 | 50,139 | +23.0% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Cost Of Sales | 61,189 | 49,579 | +23.4% |
| Developed Technology Rights | 61,189 | 49,579 | +23.4% |
| Licensing Agreements | 492 | 560 | -12.1% |
| Selling General And Administrative Expenses | 492 | 560 | -12.1% |
| Other Non-Current Assets | 104,243 | 149,891 | -30.5% |
| Assets Noncurrent | 1,952,339 | 1,945,034 | +0.4% |
| Total Assets | 8,553,619 | 5,841,526 | +46.4% |
| Long Term Investments | 65,985 | 121,144 | -45.5% |
| Current Liabilities | |||
| Accounts Payable | 423,546 | — | — |
Show Counterparty Name breakouts |
|||
| Amgen, Inc · Related Party | 135,273 | — | — |
| Accrued Liabilities | 1,079,283 | 692,179 | +55.9% |
| Taxes Payable Current | 63,522 | 34,144 | +86.0% |
| Operating Lease Liability Current | 20,584 | 18,303 | +12.5% |
| Research And Development Cost Share Liability Current Portion | 35,700 | 111,127 | -67.9% |
| Long Term Debt Royalty Liability Current | 72,735 | — | — |
| Current Portion of Long-Term Debt | 116,140 | — | — |
| Total Current Liabilities | 1,811,510 | 1,983,721 | -8.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 962,515 | — | — |
| Long Term Debt Royalty Liability Noncurrent | 831,664 | — | — |
| Operating Lease Liabilities | 49,670 | 54,895 | -9.5% |
| Deferred Tax Liabilities | 55,866 | 43,110 | +29.6% |
| Other Non-Current Liabilities | 81,952 | 65,629 | +24.9% |
| Liabilities Noncurrent | 1,981,667 | 358,292 | +453.1% |
| Total Liabilities | 3,793,177 | — | — |
Show Debt Instrument breakouts |
|||
| Royalty Payments | 904,399 | — | — |
| Long-Term Debt | 842,920 | — | — |
Show Debt Instrument breakouts |
|||
| Long Term Bank Loan Maturing January 2029 · China Merchants Bank | 18,225 | — | — |
| Long Term Bank Loan Maturing July 2032 · China CITIC Bank | 55,450 | — | — |
| Long Term Bank Loan Maturing June 2027 · China Construction Bank | 21,746 | — | — |
| Long Term Bank Loan Maturing November 2029 · China Merchants Bank | 24,174 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Loans Payable | 119,595 | — | — |
| Stockholders' Equity | |||
| Common Stock | 144 | 140 | +2.9% |
| Additional Paid-In Capital | 12,906,326 | 12,247,260 | +5.4% |
| Accumulated Other Comprehensive Income | -53,482 | -142,321 | +62.4% |
| Retained Earnings | -8,092,546 | -8,605,566 | +6.0% |
| Total Stockholders' Equity | 4,760,442 | 3,499,513 | +36.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -53,482 | -142,321 | +62.4% |
| Accumulated Translation Adjustment | -41,782 | -129,111 | +67.6% |
| Additional Paid In Capital | 12,906,326 | 12,247,260 | +5.4% |
| Common Stock | 144 | 140 | +2.9% |
| Other Adjustments | -11,700 | — | — |
| Retained Earnings | -8,092,546 | -8,605,566 | +6.0% |
| Total Liabilities & Equity | 8,553,619 | 5,841,526 | +46.4% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 41,144 | 32,804 | +25.4% |
| Stock-Based Compensation | 123,355 | 95,478 | +29.2% |
| Amortization Of Research And Development Financing Liability | -28,645 | -19,812 | -44.6% |
| Noncash Interest Expense | 21,096 | — | — |
| Other Operating Activities Cash Flow Statement | 6,172 | 12,369 | -50.1% |
| Change in Accounts Receivable | -75,300 | -31,866 | -136.3% |
| Change in Inventory | -71,838 | 3,987 | -1901.8% |
| Increase Decrease In Other Operating Assets | 15,270 | 29,737 | -48.6% |
| Change in Accounts Payable | -42,187 | -31,568 | -33.6% |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | -16,819 | -52,360 | +67.9% |
| Increase Decrease In Other Operating Liabilities | 1,731 | 4,043 | -57.2% |
| Net Cash from Operations | 201,336 | 44,082 | +356.7% |
| Investing Activities | |||
| Capital Expenditures | -40,789 | -56,407 | +27.7% |
| Proceeds From Sale Of Other Assets Investing Activities | 27 | 1,800 | -98.5% |
| Other Investing Activities | -4,748 | -7,334 | +35.3% |
| Net Cash from Investing | -45,510 | -121,941 | +62.7% |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 9,261 | 15,659 | -40.9% |
| Financing Activities | |||
| Repayments Of Long Term Debt | -7,641 | -4,215 | -81.3% |
Show Debt Instrument breakouts |
|||
| Long Term Bank Loan Maturing January 2029 · China Merchants Bank | -2,262 | — | — |
| Long Term Bank Loan Maturing July 2032 · China CITIC Bank | -3,224 | — | — |
| Long Term Bank Loan Maturing November 2029 · China Merchants Bank | -2,155 | — | — |
| Proceeds From Short Term Debt | 58,204 | 80,000 | -27.2% |
Show Debt Instrument breakouts |
|||
| Short Term Bank Loan Maturing March 2027 · China Merchants Bank | 58,204 | — | — |
| Repayments Of Short Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Short Term Bank Loan Maturing January 2029 · China Merchants Bank | -2,262 | — | — |
| Short Term Bank Loan Maturing July 2032 · China CITIC Bank | -3,224 | — | — |
| Short Term Bank Loan Maturing November 2029 · China Merchants Bank | -2,155 | — | — |
| Repayment Of Sale Of Future Royalty Liability | -2,557 | — | — |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 23,875 | 63,359 | -62.3% |
| Proceeds From Payments For Other Financing Activities | -3,249 | — | — |
| Net Cash from Financing | 68,632 | -33,777 | +303.2% |
| Amortization of Financing Costs | 2,600 | — | — |
| Supplemental | |||
| Restricted Cash And Cash Equivalents At Carrying Value | 40,839 | 11,333 | +260.4% |
| Restricted Cash And Cash Equivalents Noncurrent | 20,910 | 2,847 | +634.5% |
| Income Taxes Paid | -2,737 | 9,321 | -129.4% |
| Interest Paid | 12,834 | 6,247 | +105.4% |
| Unpaid Capital Expenditures | 43,249 | 60,010 | -27.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 19,320 | 3,480 | +455.2% |
| Net Change in Cash | 243,778 | -108,156 | +325.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4,853,425 | 2,530,591 | +91.8% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.